Pharmacist prescribing of COVID-19 antiviral treatment now available at CVS Pharmacy®
CVS Pharmacy® today announced that pharmacists at more than 9,000 CVS Pharmacy locations can clinically assess COVID-19 positive patients and, if eligible, prescribe Paxlovid, an oral antiviral treatment. In July, the Food and Drug Administration (FDA) recognized the clinical capabilities of pharmacists and granted them the authority to evaluate patients with COVID-19 and prescribe Paxlovid to clinically eligible patients. After evaluating the FDA's guidance and implementing required systems, policies, and training, CVS Pharmacy is now offering the service in 49 states, Washington, D.C., and Puerto Rico
Pharmacists can assess eligible COVID-19 positive patients and prescribe oral antiviral medication at most locations
CVS Pharmacy first to offer the service nationwide
WOONSOCKET, R.I., Nov. 15, 2022 /PRNewswire/ -- CVS Pharmacy® today announced that pharmacists at more than 9,000 CVS Pharmacy locations can clinically assess COVID-19 positive patients and, if eligible, prescribe Paxlovid, an oral antiviral treatment. In July, the Food and Drug Administration (FDA) recognized the clinical capabilities of pharmacists and granted them the authority to evaluate patients with COVID-19 and prescribe Paxlovid to clinically eligible patients. After evaluating the FDA's guidance and implementing required systems, policies, and training, CVS Pharmacy is now offering the service in 49 states, Washington, D.C., and Puerto Rico.
"Enabling pharmacists to evaluate patients and prescribe Paxlovid when clinically appropriate increases patient access and reduces barriers to care and treatment for those who need it," said Prem Shah, PharmD, Executive Vice President, CVS Health®, and President and Chief Pharmacy Officer, CVS Pharmacy. "Paxlovid has proven to be an important tool in the fight against COVID-19 by helping to reduce the severity of symptoms in patients at high risk for severe cases of the illness."
